Navigation Links
Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations

PALATINE, Ill., March 5 /PRNewswire-FirstCall/ -- Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) reported 2007 fourth quarter net income of $9.5 million, or $0.20 per diluted share compared to net income of $3.9 million, or $0.44 loss per diluted share (after giving effect to the non-cash deemed dividend discussed below) for the same quarter in 2006. For the year ended December 31, 2007, the Company reported a net loss of $4.3 million, or $0.11 per share compared to a net loss of $6.0 million, or $0.75 per share for 2006. The results for the quarter and year ended December 31, 2007 include a $9.6 million income tax benefit, or $0.21 per share. The 2007 loss includes non- cash charges of $5.4 million compared to a gain of $6.4 million in 2006 on fair value changes in common stock warrants and conversion features relating to the Company's bridge loans. The net loss per share for the quarter and year ending December 31, 2006 reflect a non-cash deemed dividend of $20.0 million and $19.2 million, respectively.

The 2007 results include certain revenues relating to the license, development and commercialization agreement (the "Agreement") closed in December, 2007 with King Pharmaceuticals Research and Development, Inc. ("King"), a wholly-owned subsidiary of King Pharmaceuticals, Inc. We classify such revenues as (i) Program Fee Revenue derived from the non-refundable $30.0 million upfront payment received in December, 2007 and which will be recognized ratably over our estimate of the development period for each of the product candidates licensed under the Agreement with King; and (ii) Collaboration Revenue from reimbursement of research and development expenses. The 2007 results include the recognition of $3.4 million and $3.0 million of Program Fee Revenue and Collaboration Revenue, respectively.

As of March 1, 2008, the Company had cash and cash equivalents of approximately $31 million with no term indebtedness. The majority of our cash reserves will be used to develop additional Aversion(R) Technology product candidates, prosecute our pending Aversion(R) Technology patent applications and for related operating and business development expenses.

The Company's condensed consolidated balance sheet and statements of operation appear below. All reported share and per share data have been adjusted to reflect a one-for-ten reverse stock split effected on December 5, 2007. Detailed financial statements are included in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission.

2007 Accomplishments and 2008 Expectations

Andy Reddick, President and CEO of Acura said, "In 2007 several of the key strategic initiatives that we have been focused on for several years resulted in tangible and positive outcomes. We are pleased to report that the Company is steadily advancing toward our goal of becoming a leading specialty pharmaceutical company focused on addressing the growing societal problem of prescription drug abuse. 2007 achievements included:

-- April, 2007 - received from the U.S. Patent and Trademark Office our

first issued US Patent encompassing Aversion(R) (abuse deterrent)

Technology which we believe will provide patent protection in the U.S.

for Aversion(R) Technology opioid products at least through the year


-- June, 2007 - reached agreement with the FDA for a Special Protocol

Assessment for the Company's pivotal phase III safety and efficacy

clinical study for Acurox(TM) Tablets, our lead product candidate

-- August, 2007 - completed a private placement of Company securities

resulting in elimination of $10.5 million in debt and $14.2 million of

new capital to the Company

-- September, 2007 - commenced our pivotal Phase III safety and efficacy

study for Acurox(TM) Tablets

-- October, 2007 - signed a major License, Development and

Commercialization Agreement with King resulting in receipt of a non

refundable $30.0 million payment in December, 2007, plus reimbursement

of Acurox(TM) Tablet research and development expenses from September

19, 2007, and expected future milestone payments and royalties relating

to product candidates licensed to King under the Agreement

-- December, 2007 - filed an application with NASDAQ resulting in the

Company's listing on the NASDAQ Capital Market effective February 4,


In 2008 we will remain focused on execution of our strategy and among other things expect to:

-- Submit an IND to the FDA for our second Aversion(R) Technology opioid

product candidate in the first half of 2008

-- Report top line results for our Acurox(TM) Tablet pivotal Phase III

safety and efficacy study prior to the end of the third quarter of 2008

-- Submit to the FDA a 505(b)(2) NDA for Acurox(TM) Tablets prior to the

end of 2008"

About Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of innovative Aversion(R) (abuse deterrent) Technology and related product candidates.

Forward Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our Company's expectations and projections. The most significant of such risks and uncertainties include, but are not limited to, our ability, and the ability of King Pharmaceuticals Research and Development, Inc. and other pharmaceutical companies, if any, with whom we may license our Aversion(R) Technology, to obtain necessary regulatory approvals and commercialize products utilizing the Aversion(R) Technology, the ability to avoid infringement of patents, trademarks and other proprietary rights or trade secrets of third parties, and the ability to fulfill the FDA's requirements for approving our product candidates for commercial manufacturing and distribution in the United States, including, without limitation, the adequacy of the results of the clinical studies completed to date and the results of other clinical studies, to support FDA approval of our product candidates, the adequacy of the development program for our product candidates, changes in regulatory requirements, adverse safety findings relating to our product candidates, the risk that the FDA may not agree with our analysis of its clinical studies and may evaluate the results of these studies by different methods or conclude that the results of the studies are not statistically significant, clinically meaningful or that there were human errors in the conduct of the studies or otherwise, the risk that further studies of our product candidates are not positive, and the uncertainties inherent in scientific research, drug development, clinical trials, the regulatory approval process, and commercial supply. You are encouraged to review other important risk factors relating to our operations on our web site at under the link, "Company Risk Factors" and detailed in our filings with the Securities and Exchange Commission. We assume no obligation to update any forward-looking statements as a result of new information or future events or developments. Our press releases may be reviewed at



(in thousands)


at December 31,

2007 2006

Current Assets $ 44,582 $ 467

Property, Plant and

Equipment, net 1,046 1,145

Other Assets - 7

Total Assets $ 45,628 $ 1,619

Accrued Expenses 334 328

Stock Warrants - 10,784

Debt, net - 28,787

Stockholders' Equity (Deficit) 18,720 (38,280)

Total Liabilities and

Stockholders' Deficit $ 45,628 $ 1,619



(in thousands, except per share data)

(unaudited) (audited)

Three Mths Twelve Mths

Ended Dec 31, Ended Dec 31,

2007 2006 2007 2006

Total Revenues

Program Fee Revenue $ 3,427 $ - $ 3,427 $ -

Collaboration Revenue 2,977 - 2,977 -

Total Revenues 6,404 - 6,404 -

Operating Costs

Research and Development 4,394 997 7,169 5,172

Marketing, General and

Administrative 2,182 900 4,141 5,654

Total Operating Expenses 6,576 1,897 11,310 10,826

Loss from Operations (172) (1,897) (4,906) (10,826)

Other Income (Expense)

Interest Income 188 4 268 18

Interest Expense (94) (340) (1,207) (1,140)

Amortization of Debt Discount - (183) (2,700) (183)

Gain (Loss) on Fair Value

Change of Conversion Features - 4,235 (3,483) 4,235

Gain (Loss) on Fair Value Change

of Common Stock Warrants - 2,164 (1,905) 2,164

Gain (Loss) on Asset Disposals - (71) 22 (22)

Other Expense (1) (12) (3) (213)

Total Other Income

(Expense) 93 5,797 (9,008) 4,859

Income (Loss) Before Income

Tax Benefit (79) 3,900 (13,914) (5,967)

Income Tax Benefit (9,600) - (9,600) -

Net Income (Loss) $ 9,521 $ 3,900 $ (4,314) $ (5,967)

Income (Loss) Per

Common Share Applicable

to Common Stockholders

Basic $ 0.21 $ (0.44) $ (0.11) $ (0.75)

Diluted $ 0.20 $ (0.44) $ (0.11) $ (0.75)

Weighted Average Number of

Outstanding Common Shares 45,488 34,864 39,157 34,496

SOURCE Acura Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
2. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
3. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
5. Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc.
6. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
7. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
8. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
9. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
10. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
11. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/9/2017)... FL (PRWEB) , ... October 09, 2017 , ... The ... scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... industry is faced with the challenge of how to continue to feed a growing ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... for microscopy and surface analysis, Nanoscience Instruments is now expanding into Analytical ... broad range of contract analysis services for advanced applications. Services will leverage ...
(Date:10/6/2017)... , ... October 06, 2017 , ... ... a lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for ... Dana-Farber Cancer Institute. The event is free and open to the public, but ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at ... . 2016 Year Highlights: ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
Breaking Biology News(10 mins):